8-K: INVO Bioscience Granted Nasdaq Extension, Subsidiary Transfers Ownership of Medical Practice

INVO Bioscience has been granted an extension by Nasdaq to regain compliance with listing rules, while a subsidiary transferred ownership of a medical practice.

Summary

• INVO Bioscience received a notice from Nasdaq on June 18, 2024, granting an extension to demonstrate compliance with listing rules.
• The company was previously notified of potential delisting due to not meeting the minimum stockholders' equity requirement of $2,500,000.
• INVO Bioscience requested an extension until October 14, 2024, to complete the acquisition of NAYA Biosciences, Inc. and meet Nasdaq's initial listing requirements.
• On June 13, 2024, INVO's subsidiary, Wood Violet Fertility, LLC, transferred ownership of Wisconsin Fertility and Reproductive Surgery Associates, S.C. to Donna Baldwin, D.O.
• The former owner, officer, and director of WFRSA, Dr. Elizabeth Pritts, M.D., separated from employment on the same day.
• The transfer and separation are not expected to impact patient care or the financial performance of Wisconsin Fertility Institute.
• INVO believes the transfer and separation will not materially impact the company's financial condition or results of operation.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The extension from Nasdaq is positive, but the underlying issue of non-compliance and the need for an acquisition to meet listing requirements are concerning. The transfer of the medical practice is neutral.

Positives

• INVO Bioscience received an extension from Nasdaq, avoiding immediate delisting.
• The company has until October 14, 2024, to regain compliance with listing requirements.
• The transfer of ownership of the medical practice is not expected to impact patient care or financial performance.

Negatives

• INVO Bioscience was previously notified of potential delisting due to not meeting the minimum stockholders' equity requirement of $2,500,000.
• The company was not eligible for the standard 180-day compliance period due to prior non-compliance issues.

Risks

• INVO Bioscience must complete the acquisition of NAYA Biosciences, Inc. and meet Nasdaq's initial listing requirements by October 14, 2024.
• Failure to meet these requirements could result in delisting from Nasdaq.
• The company's financial condition remains under scrutiny due to previous non-compliance with equity rules.

Future Outlook

INVO Bioscience is focused on completing the acquisition of NAYA Biosciences, Inc. and regaining compliance with Nasdaq listing requirements by October 14, 2024.

Management Comments

• The Company believes that the transfer and separation will not materially impact the Company's financial condition or results of operation.
• The Company believes that the extension is sufficient time to complete its proposed acquisition of NAYA Biosciences, Inc. and satisfy Nasdaq's initial listing requirements.

Industry Context

The document highlights the challenges faced by smaller biotech companies in maintaining Nasdaq listing compliance, particularly regarding financial metrics. It also shows the complexities of managing subsidiary operations and acquisitions.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum equity requirements.
• The 180-day compliance period is a standard process for companies that fall below the minimum equity requirement, however, INVO was not eligible due to previous non-compliance.
• The acquisition of NAYA Biosciences is a common strategy for companies seeking to improve their financial position and meet listing requirements.

Management Changes

Stakeholder Impact

• Shareholders are impacted by the potential delisting and the need for the company to regain compliance.
• Patients of Wisconsin Fertility Institute are not expected to experience any changes in care.
• Employees of WFRSA may be impacted by the change in ownership and management.

Next Steps

• INVO Bioscience must complete the acquisition of NAYA Biosciences, Inc.
• The company must demonstrate compliance with Nasdaq's listing rules by October 14, 2024.

Key Dates

Keywords

Nasdaq, delisting, compliance, listing rules, stockholders equity, acquisition, medical practice, INVO Bioscience, NAYA Biosciences, Wisconsin Fertility Institute